955 / 1119
G≥1: 89%
G≥2: 29%
G≥3: 4%
Vaginal morbidity after definitive
radiochemotherapy + IGABT in LACC
• N=588 LACC within EMBRACE
study
• Prospective assessment of
morbidity (CTCAE 3)
at baseline and regular follow-ups
(median 15 months)
• Endpoints: vaginal stenosis,
dryness, mucositis, bleeding,
fistula
Kirchheiner et al.
IJROBP 2014